AbCellera Biologics (ABCL)
Discovers antibodies for partners and advances its own clinical candidates.
Something off on this page? Send us feedback.
Builds antibody medicines through an integrated discovery platform and a growing internal pipeline. Its strategy emphasizes AbCellera-owned assets while selected partner programs remain active.
Combines technology, data science, infrastructure, and interdisciplinary teams to discover and develop antibody-based medicines. The platform historically supported partner programs, including antibodies discovered with Lilly for COVID-19, while the company now advances AbCellera-owned candidates. Its clinical pipeline spans endocrinology, women's health, immunology, and oncology, with ABCL635 and ABCL575 in clinical trials.
Founded in Vancouver, the workforce spans Canada, Australia, and the United States. Founder and CEO Carl Hansen has led the company since inception, and co-founder Véronique Lecault is chief technology officer. The operating model integrates antibody discovery with internal clinical development while selected partner-led programs remain active.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 11, 2026 | Truist Financial | Target | Target: $29 | Target: $30 |
| Aug 6, 2026 | Stifel Nicolaus | Target | Target: $8 | Target: $9 |
| Jul 7, 2026 | Benchmark | Upgrade | ||
| May 12, 2026 | Stifel Nicolaus | Target | Target: — | Target: $8 |
| May 5, 2026 | Cantor Fitzgerald | Target | Target: — | Target: $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $540.1M · Total debt $135.6M · Total assets $1.31B · Shareholders' equity $896.0M
- Revenue
- $4.1M
- Operating income
- −$62.8M
- Net income
- −$55.4M
No dividends on record.
| Institutions | ≈ 37.66% | 115.46M shares | |
|---|---|---|---|
| 167 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 19.46% | 59.67M shares | |
| 5 holders · as of Aug 24, 2026 | |||
| Strategic holders | 18.31% | 56.13M shares | |
| 1 holder · as of Mar 2, 2026 | |||
| Other | ≈ 24.57% | 75.34M shares | |
| remainder | |||
306.61M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Carl L. G. Hansen1Insiderdirector, 10 percent owner, officer: Chief Executive Officer | 18.50% | 61.83M | filed Nov 26, 2024 |
Thermopylae Holdings Ltd.Strategic10 percent owner | 18.31% | 56.13M | filed Mar 2, 2026 |
Baker Bros. Advisors LPInstitution | 10.77% | 33.01M | as of Jun 30, 2026 |
Capital World InvestorsInstitution | 4.43% | 13.59M | as of Jun 30, 2026 |
Two Sigma Investments, LPInstitution | 3.40% | 10.44M | as of Jun 30, 2026 |
- Carl L. G. Hansen's transaction reports restate only vehicles that traded; the 2021 ownership statement (61.83M) less the 5.10M net shares sold since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 24, 2026 | Michael R. Hayden | director | +53,613 | $10.64 |
| Aug 18, 2026 | John S. Montalbano | director | +10,000 | $11.03 |
| Aug 14, 2026 | Andrew Booth | officer: Chief Financial Officer | +37,200 | $10.32 |
| Aug 12, 2026 | Michael R. Hayden | director | +46,387 | $10.37 |
| May 14, 2026 | John S. Montalbano | director | +20,000 | $4.77 |
- OmniAb
Transgenic antibody-discovery platform for biopharma partners
- Absci
AI-native antibody discovery and clinical-stage therapeutic development
- Genmab (ADR)
Antibody technology platforms, partnerships, and proprietary medicines
- Twist Bioscience
Synthetic antibody-library discovery services for therapeutic programs
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AbCellera Biologics | $12.41 | −1.90% | $3.86B | — | — | 58.4 | −76.3% |
| OmniAb | $4.96 | +0.71% | $713.3M | — | — | 18.6 | +244.2% |
| Absci | $10.17 | −5.04% | $1.81B | — | — | 1,162.3 | −49.4% |
| Genmab (ADR) | $35.41 | +0.53% | $21.62B | 27.8 | 27.0 | 5.2 | +24.9% |
| Twist Bioscience | $163.76 | −0.51% | $10.25B | — | — | 23.7 | +23.3% |
| Median | 27.8 | 27.0 | 21.1 | +24.1% |